A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...

Philadelphia, November 18, 2021—A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete ...

Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...

Scientists have solved a mystery about where the body stores and deploys blood-clotting factor VIII, a protein that about 80 percent of hemophiliacs cannot produce due to genetic defects. For years, ...

The bleeding disorder hemophilia A, inherited by one in 5000 males, is caused by the lack or malfunction of a blood coagulating factor, factor VIII, encoded by a gene on the X chromosome. The clotting ...

Rare clotting factor deficiencies are a collection of bleeding disorders associated with issues with clotting factors. These conditions are inherited and target the proteins in the blood that control ...

Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short ...

Detailed coagulation analyses in 36 pediatric cases of septicemia revealed 22 gram-negative and eight gram-positive infections, two Rocky Mountain spotted fevers, and four with no etiologic agent ...